| Item type |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2021-08-20 |
| タイトル |
|
|
タイトル |
Erlotinib and bevacizumab in elderly patients ?75 years old with non-small cell lung cancer harboring epidermal growth factor receptor mutations |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| キーワード |
|
|
主題 |
bevacizumab |
| キーワード |
|
|
主題 |
elderly patients |
| キーワード |
|
|
主題 |
epidermal growth factor receptor mutation |
| キーワード |
|
|
主題 |
erlotinib |
| キーワード |
|
|
主題 |
targeted therapy |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 著者 |
Aoshima, Yoichiro
Karayama, Masato
Inui, Naoki
Yasui, Hideki
Hozumi, Hironao
Suzuki, Yuzo
Furuhashi, Kazuki
Fujisawa, Tomoyuki
Enomoto, Noriyuki
Nakamura, Yutaro
Mikamo, Masashi
Matsuura, Shun
Kusagaya, Hideki
Kaida, Yusuke
Uto, Tomohiro
Hashimoto, Dai
Matsui, Takashi
Asada, Kazuhiro
Suda, Takafumi
|
| 書誌情報 |
Investigational New Drugs
巻 39,
号 1,
p. 210-216,
発行日 2021-02
|
| 出版者 |
|
|
出版者 |
Springer Nature |
| 権利 |
|
|
権利情報 |
"This is a post-peer-review, pre-copyedit version of an article published in ""Investigational New Drugs"". The final authenticated version is available online at: https://doi.org/10.1007/s10637-020-00988-1." |
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Purpose: The efficacy and safety of combination therapy with erlotinib and bevacizumab in elderly patients with non-small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) gene mutations are unknown.
Methods: Elderly patients aged ?75 years old with advanced or recurrent NSCLC and EGFR mutations (exon 19 deletion or L858R mutation in exon 21) received erlotinib (150 mg, daily) and bevacizumab (15 mg/kg on day 1 of a 21-day cycle) until disease progression or the occurrence of unacceptable toxicities. The primary endpoint was progression-free survival from enrollment.
Results: Twenty-five patients were enrolled in this study, and the median age was 80 years. Fifteen (60.0%) and 10 patients (40.0%) had exon 21 L858R mutations and exon 19 deletions, respectively. The median progression-free survival from enrollment was 12.6 months [95% confidence interval (CI): 8.0?33.7 months]. The objective response rate was 88.0% [95% CI: 74.0%?99.0%], and the disease control rate was 100% [95 % CI: 88.7%?100%]. Grade 3 or higher adverse events occurred in 12 patients (48.0%), and rash and nausea were the most common. Grade 3 or higher bevacizumab-related toxicities occurred in 4 (16.0%) patients, including proteinuria (n=2), gastrointestinal perforation (n=1) and pneumothorax (n=1). A dose reduction of erlotinib and cessation of bevacizumab was required in 16 (64.0%) and 18 patients (72.0%), respectively.
Conclusion: Erlotinib and bevacizumab combination therapy showed a minimal survival benefit with frequent dose reductions and/or treatment discontinuations in elderly patients with EGFR-positive NSCLC. |
| ISSN |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
0167-6997 |
| EISSN |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
1573-0646 |
| PubMed番号 |
|
|
関連タイプ |
isVersionOf |
|
|
識別子タイプ |
PMID |
|
|
関連識別子 |
32803701 |
| 出版社DOI |
|
|
関連タイプ |
isVersionOf |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
10.1007/s10637-020-00988-1 |
| 著者版フラグ |
|
|
出版タイプ |
AM |
|
出版タイプResource |
http://purl.org/coar/version/c_ab4af688f83e57aa |
IND-39-210.pdf (612.6 kB)
